Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Will novel oral formulations change the management of inflammatory bowel disease?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Mometasone furoate nasal spray for the treatment of asthma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Lixisenatide for type 2 diabetes mellitus

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Serotonin 2A receptor antagonists for treatment of schizophrenia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Gut Mucosal Gene Expression and Metabolic Changes After Roux-en-Y Gastric Bypass Surgery

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The role of endogenous GIP and GLP-1 in postprandial bone homeostasis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer
The incretin hormones are intestinal peptides that enhance insulin secretion following ingestion of nutrients. Liraglutide is a glucagon-like peptide-1 receptor analogue, which is obtained by derivatising glucagon-like peptide-1 with a fatty acid, providing a compound with pharmacokinetic properties that are suitable for once-daily dosing. Liraglutide has demonstrated lasting improvement of HbA(1c )levels, weight reduction and improved beta-cell function in patients with Type 2 diabetes mellitus. Liraglutide is well tolerated; the adverse events that are most frequently reported being transient nausea and diarrhoea. This article reviews the mechanisms of action and efficacy of liraglutide for the treatment of Type 2 diabetes mellitus. This agent is presently in Phase III clinical development.
OriginalsprogEngelsk
TidsskriftExpert Opinion on Investigational Drugs
Vol/bind16
Udgave nummer2
Sider (fra-til)231-7
Antal sider7
ISSN1354-3784
DOI
StatusUdgivet - 1 feb. 2007

ID: 32268071